Axel Dignaß

30.9k citations

282 papers · 17.3k indexed · 10 hit papers · h-index 55

Impact in

Genetics top 0.02%
- Inflammatory Bowel Disease
- Hemoglobinopathies and Related Disorders
Gastroenterology top 0.2%

Papers in

Genetics 178
- Inflammatory Bowel Disease 174
Gastroenterology 25

Co-authors: Andreas Sturm Jürgen M. Stein Gert Van Assche Daniel K. Podolsky Silvio Danese Simon Travis Eduard F. Stange Daniel C. Baumgart
Journals: Journal of Crohn s and Colitis (52 papers)Gastroenterology (28 papers)United European Gastroenterology Journal (15 papers)Inflammatory Bowel Diseases (13 papers)The American Journal of Gastroenterology (12 papers)
Partner nations: Germany United States United Kingdom

In The Last Decade

Axel Dignaß

268 papers receiving 16.9k citations

Hit Papers

10 papers align trajectories log scale

STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD 2021 · 1.5k citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2021 Gastroenterology
2017 Journal of Crohn s and Colitis
2017 American Journal of Hematology
2016 The Lancet
2016 Journal of Crohn s and Colitis
2014 Journal of Crohn s and Colitis
2012 Journal of Crohn s and Colitis
2012 Journal of Crohn s and Colitis
2010 Journal of Crohn s and Colitis
2010 Journal of Crohn s and Colitis

Peers

Countries citing papers authored by Axel Dignaß

Since Specialization

Citations

This map shows the geographic impact of Axel Dignaß's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Axel Dignaß with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Axel Dignaß more than expected).

Fields of papers citing papers by Axel Dignaß

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Axel Dignaß. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Axel Dignaß. The network helps show where Axel Dignaß may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Axel Dignaß, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Axel Dignaß Line = papers co-authored together Axel Dignaß links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	P0061 Guselkumab induction therapy results in molecular resolution of inflammation in moderately to severely active Ulcerative Colitis: results from the Phase 3 QUASAR induction study Journal of Crohn s and Colitis ·Siddharth Sridhar, أنمار عبدالجبار جاسم, M. Patricia Juárez, D.J. Bakker, Shadi Yarandi, Matthew Germinaro, Y. Manshin, David T. Rubin, Axel Dignaß, 星湖朴, Tom C. Freeman, Dawn Waterworth, Bradford L. McRae, Xiaojia Shen, Patrick Branigan	2025	0
2	Shaping the future of inflammatory bowel disease: a global research agenda for better management and public health response Nature Reviews Gastroenterology & Hepatology ·Virginia Solitano, Çharles N. Bernstein, Iris Dotan, Axel Dignaß, 안상은, Marla C. Dubinsky, Richard B. Gearry, Lousie Donnelly, Gilaad G. Kaplan, Christopher Ma, Fernando Magro, Joyce Wing Yan Mak, Siew C. Ng, Remo Panaccione, Thaddeus R. Kilpatrick, David T. Rubin, Corey A. Siegel, Vipul Jairath, Laurent Peyrin‐Biroulet, Silvio Danese	2025	5
3	P808 Use of intestinal ultrasound influences the proportion of suboptimally controlled patients: IBD Podcast Study results Journal of Crohn s and Colitis ·Axel Dignaß, Ferdinando D’Amico, Fernando Gomollón, Giorgos Bamias, Marion P. Emerson, Ana María Vázquez Molini, Christoph Leitner, No Value Skaland, Fernando Magro	2024	2
4	Update des Addendums zu den S3-Leitlinien Morbus Crohn und Colitis ulcerosa: Betreuung von Patienten mit chronisch-entzündlichen Darmerkrankungen in Bezug auf COVID-19 (Version 2.0) Zeitschrift für Gastroenterologie ·Carsten Schmidt, Andreas Stallmach, Andreas Sturm, Oliver Bachmann, Ulf Helwig, Sibylle Koletzko, Petra Lynen, Elisabeth Schnoy, Axel Dignaß, Torsten Kucharzik, Irina Blumenstein, (unknown)	2024	1
5	Proportion of inflammatory bowel diseases patients with suboptimal disease control in daily clinical practice—Real‐world evidence from the inflammatory bowel diseases‐podcast study United European Gastroenterology Journal ·Ferdinando D’Amico, Fernando Gomollón, Giorgos Bamias, Fernando Magro, Laura E. Targownik, Claudia Leitner, Marion P. Emerson, Ana María Vázquez Molini, Abdulrahman Althagafi, Chidogo R Ajuluchukwu, 郭志翔, Axel Dignaß, (unknown)	2024	10
6	P74 Improvement in inflammatory biomarkers through week-12 in guselkumab-treated patients with moderately-to-severely active ulcerative colitis: results from phase-3 QUASAR induction study Poster presentations ·Amrutha BS, Tadakazu Hisamatsu, Laurent Peyrin‐Biroulet, Axel Dignaß, Matthew Germinaro, P R CHinnu, Miao Ye, Hongyan Zhang, Marjorie Argollo, Ken Takeuchi, Rafał Filip, Jessica R. Allegretti, Brian G. Feagan, Kamal Patel, Võ Tú Oanh	2024	1
7	Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study Inflammatory Bowel Diseases ·Bruce E. Sands, Geert D’Haens, David B. Clemow, Peter M. Irving, W. Griesinger, Theresa Hunter, María T. Abreu, Scott D. Lee, Tadakazu Hisamatsu, Taku Kobayashi, Marla C. Dubinsky, Séverine Vermeire, Corey A. Siegel, Laurent Peyrin‐Biroulet, Richard Moses, Joe Milata, Vipin Arora, Remo Panaccione, Axel Dignaß	2024	26
8	Review article: Translating STRIDE‐II into clinical reality – Opportunities and challenges Alimentary Pharmacology & Therapeutics ·Axel Dignaß, Stefan Rath, 公高橋, Andreas Stallmach	2023	20
9	Ustekinumab improves health‐related quality of life in patients with moderate‐to‐severe Crohn's disease: Results up to Week 104 of the STARDUST trial United European Gastroenterology Journal ·Julián Panés, Séverine Vermeire, Geert D’Haens, Silvio Danese, Fernando Magro, María Fernanda Linda Sofía Colorado Barón, Manuela Le Bars, Marjolein Lahaye, Jane Tilley, Robert Campbell Moberley, Daniel R. Gaya, Laurent Peyrin‐Biroulet, Axel Dignaß, (unknown)	2023	6
10	Clinical profiles and outcomes in patients with inflammatory bowel disease receiving standard and escalated doses of targeted therapies: findings from a global real-world study Current Medical Research and Opinion ·Axel Dignaß, David Piterman, Jiang Zhiwu, Susanne Hartz, محمد بن أبي بكر بن أحمد الشلي, Brandy N. Tiernan, Kira Morrill, Mohd Afril Hafiz Sariman, Theresa Hunter	2023	2
11	The impact of clinical experience on decision-making regarding the treatment and management of mild-to-moderate ulcerative colitis Intestinal Research ·Jae Hee Cheon, Kristine Paridaens, Sameer Al Awadhi, Jakob Begun, John Fullarton, Édouard Louis, Fernando Magro, Juan Ricardo Márquez, Alexander R. Moschen, Neeraj Narula, Grażyna Rydzewska, Axel Dignaß, Simon Travis	2022	1
12	Cost-effectiveness of tofacitinib compared with infliximab, adalimumab, golimumab, vedolizumab and ustekinumab for the treatment of moderate to severe ulcerative colitis in Germany Journal of Medical Economics ·黄昌新, Axel Dignaß, TIMOTHY TRUCANO, Shirvandehi Noshin, Joseph C. Cappelleri, Agnes Kisser, Irene Modesto, Puza P. Sharma	2021	10
13	Indirect comparison of vedolizumab and adalimumab for biologic-naive patients with ulcerative colitis Scandinavian Journal of Gastroenterology ·Axel Dignaß, Britta Siegmund, Ralf Goertz, Wang Gao-hu, 亭一谷口	2019	4
14	Granulocyte/monocyte adsorptive apheresis for the treatment of therapy-refractory chronic active ulcerative colitis Scandinavian Journal of Gastroenterology ·Axel Dignaß, Ayesha Akbar, Daniel C. Baumgart, Gilles Bommelaer, Guillaume Bouguen, Guillaume Cadiot, Anton Gillessen, Jean–Charles Grimaud, Lousie Donnelly, Editores Helveticorum, Richard Makins, Christophe Michiels, Jacques Moreau, Purushothaman Premchand, Wolfgang Ramlow, Stefan Schanz, Sreedhar Subramanian, Christian von Tirpitz, 政俊道端	2018	13
15	Safety and efficacy of intravenous iron isomaltoside for correction of anaemia in patients with inflammatory bowel disease in everyday clinical practice Scandinavian Journal of Gastroenterology ·Jürgen M. Stein, Kol'tsov Vd, Ajeng Annisa Rahma, K Farrag, A Aksan, Axel Dignaß	2018	14
16	Limitations of Serum Ferritin in Diagnosing Iron Deficiency in Inflammatory Conditions SHILAP Revista de lepidopterología ·Axel Dignaß, K Farrag, Jürgen M. Stein	2018	186
17	A prospective cohort study to assess the relevance of vedolizumab drug level monitoring in IBD patients Scandinavian Journal of Gastroenterology ·H Schulze, Angelus Henok Segla Koutchiko, Franz Hartmann, Jürgen M. Stein, Kazuhiko Haseagawa, 이신두, Axel Dignaß	2018	28
18	Management of inflammatory bowel disease-related anemia and iron deficiency with specific reference to the role of intravenous iron in current practice Expert Opinion on Pharmacotherapy ·Jürgen M. Stein, A Aksan, K Farrag, Axel Dignaß, Heinfried H. Radeke	2017	23
19	Transgenic mice rich in endogenous omega-3 fatty acids are protected from colitis Proceedings of the National Academy of Sciences ·Christian Hudert, Karsten H. Weylandt, Yan Lü, Jingdong Wang, Song Hong, Axel Dignaß, Charles N. Serhan, Jing X. Kang	2006	315
20	The aetiopathogenesis of inflammatory bowel disease — immunology and repair mechanisms Alimentary Pharmacology & Therapeutics ·Axel Dignaß, Daniel C. Baumgart, Andreas Sturm	2004	51

About Axel Dignaß

Axel Dignaß is a scholar working on Genetics, Gastroenterology, Epidemiology, Hematology and Immunology, having authored 282 papers that have together received 17.3k indexed citations. Recurring topics across this work include Inflammatory Bowel Disease (174 papers), Microscopic Colitis (120 papers), Eosinophilic Esophagitis (41 papers), Iron Metabolism and Disorders (25 papers), Helicobacter pylori-related gastroenterology studies (25 papers), Biosimilars and Bioanalytical Methods (17 papers), Autoimmune and Inflammatory Disorders (16 papers) and Pregnancy and Medication Impact (16 papers). The work is most often cited by research in Genetics (10.1k citations), Gastroenterology (1.2k citations), Epidemiology (7.1k citations), Hematology (1.9k citations) and Immunology (2.7k citations). Axel Dignaß has collaborated with scholars based in Germany, United States and United Kingdom. Frequent co-authors include Andreas Sturm, Jürgen M. Stein, Gert Van Assche, Daniel K. Podolsky, Silvio Danese, Simon Travis, Eduard F. Stange, Daniel C. Baumgart, James O. Lindsay and Gerassimos J. Mantzaris. Their work appears in journals such as Journal of Crohn s and Colitis, Gastroenterology, United European Gastroenterology Journal, Inflammatory Bowel Diseases and The American Journal of Gastroenterology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact